Ciprofloxacin-Induced Adverse Effects

Introduction to Ciprofloxacin-Induced Adverse Effects

Ciprofloxacin can cause arthropathy in elderly patients, with increased risk compared to younger adults due to age-related factors and potential for more severe consequences, as noted by the American Geriatrics Society's Beers Criteria 1, 2

Concomitant use of corticosteroids, renal dysfunction, and history of tendon disorders related to quinolone use increase the risk of ciprofloxacin-induced arthropathy in elderly patients 3, 4
Age is a significant risk factor, with elderly patients being more susceptible to ciprofloxacin-induced arthropathy, as recommended by the American Geriatrics Society 2

Arthropathy associated with ciprofloxacin in elderly patients typically presents as joint pain, tendon inflammation and rupture, abnormal joint and/or gait examination findings, back pain, leg pain, and bone pain, with symptoms developing within days to weeks of starting ciprofloxacin 5, 3, 4
Ciprofloxacin inhibits osteoblast cell growth and extracellular matrix mineralization in a dose-dependent manner, which may explain its effects on bone and joint tissues, as supported by the American Academy of Orthopaedic Surgeons 1
Arthropathy can persist even after discontinuation of ciprofloxacin, with some studies showing persistent effects at 1 year of follow-up 5

The American Geriatrics Society recommends using the lowest effective dose of ciprofloxacin for the shortest duration to minimize the risk of arthropathy in elderly patients, as supported by the Centers for Disease Control and Prevention and the European Respiratory Society 4, 2, 6
Clinicians should carefully weigh the benefits against the risks of ciprofloxacin in elderly patients, particularly in those with additional risk factors for arthropathy, as advised by the FDA and the American Academy of Pediatrics 4, 7
Patients should avoid strenuous physical activity during treatment and maintain hydration to prevent crystalluria, while taking ciprofloxacin 1-2 hours before or 4-6 hours after products containing calcium, aluminum, magnesium, or iron, as recommended by the European Medicines Agency and the National Institute for Health and Care Excellence 3
The following table summarizes the rates of musculoskeletal adverse events:

Treatment	Rate of Musculoskeletal Adverse Events
Ciprofloxacin	9.3% (at 6 weeks), 13.7% (at 1 year)
Comparator	6.0% (at 6 weeks), 9.5% (at 1 year)
Ciprofloxacin (US)	21%

Ciprofloxacin should only be used in pregnancy when the benefits outweigh the risks, as recommended by the Centers for Disease Control and Prevention and the FDA 7, 4
Elderly patients, pediatric patients, and patients with renal dysfunction require dosage adjustment due to increased risk of adverse effects, including musculoskeletal complications, as recommended by the FDA and the American Academy of Pediatrics 4, 7
Ciprofloxacin has significant drug interactions, including antacids, calcium, iron, magnesium, aluminum, dairy products, and QT-prolonging medications, which can increase the risk of arrhythmias, as warned by the FDA and the American College of Cardiology 3, 4
Immediate discontinuation of ciprofloxacin is recommended in cases of tendinopathy, hypersensitivity reactions, and CNS effects, as recommended by the FDA 4

Arthralgia/arthritis are common adverse effects of ciprofloxacin, with a rate of 9.3% at 6 weeks and 13.7% at 1 year, and can be increased by factors such as age, renal dysfunction, and concomitant corticosteroid use 5, 4
QT interval prolongation can lead to fatal arrhythmias (torsade de pointes), and patients with a history of QT prolongation should be monitored closely, as recommended by the American College of Cardiology 3, 4
Ciprofloxacin can cause serious and occasionally fatal adverse effects, even after only one dose, including hypersensitivity reactions, seizures, and toxic psychosis, and patients should be advised to stop medication and contact their healthcare provider at the first sign of tendon pain or inflammation, as recommended by the FDA 4